[EN] CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER<br/>[FR] MONOMÉTHYL AURISTATINE E CONJUGUÉ PERMETTANT D'OBTENIR UNE COMPOSITION DESTINÉE AU TRAITEMENT DU CANCER DE LA PROSTATE
申请人:OBSHCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU IZVARINO FARMA
公开号:WO2021101407A1
公开(公告)日:2021-05-27
This invention is the conjugate of formula (I) for treatment of tumors expressing PSMA, including PSMA-ligand with linker and antineoplastic agent MMAE, the composition for lyophilizate preparation based on it, the dosage form for therapy and obtained by the lyophilization of this composition, PSMA expressing prostate tumor growth inhibition, the solution for infusions or injections containing this dosage form, reconstituted by the solvent, comprising 95% ethyl alcohol and polysorbate 80 within mass ratio (30-60):(70-40), respectively. The technical result of the claimed group of inventions is the high affinity and selectivity of the action of the claimed conjugates in relation to PSMA expressing cells. 6 files of independent points and 6 files of dependent points, 15 illustrations, 27 tables, 7 notes.
这项发明是用于治疗表达PSMA的肿瘤的公式(I)的共轭物,包括具有连接剂和抗肿瘤剂MMAE的PSMA配体,基于此的冻干制剂制备的组合物,用于治疗的剂型以及通过该组合物的冻干制剂制备的,PSMA表达的前列腺肿瘤生长抑制,注射或静脉注射的溶液,含有该剂型,通过溶剂重组成的,包含95%乙醇和聚山梨醇酯80的质量比(30-60):(70-40),所述申请的一组发明的技术效果是所述共轭物对PSMA表达细胞具有高亲和力和选择性作用。6个独立点的文件和6个依赖点的文件,15个插图,27个表格,7个注释。